J Appl Biomed X:X | DOI: 10.32725/jab.2025.017

Relationship between interleukin-37 genetic polymorphisms and HBV-related liver disease in a Chinese Han cohort

Ping Fang1, *, Ping Meng2, Lijun Du1, Hui Li3, Rong Wang1, Juan Zhao1, Decheng Cai4, *
1 Huadu District People's Hospital of Guangzhou, Department of Medical laboratory, Guangzhou, Guangdong, China
2 Huadu District People's Hospital of Guangzhou, Department of Central Laboratory, Guangzhou, Guangdong, China
3 Huadu District People's Hospital of Guangzhou, Department of Internal Medicine, Guangzhou, Guangdong, China
4 The Third Affiliated Hospital of Southern Medical University, Department of Medical Laboratory, Guangzhou, Guangdong, China

Hepatitis B virus (HBV)-related liver disease is an inflammatory-associated disease, with diverse clinical phenotypes ranging from asymptomatic HBV carriers to hepatocellular carcinoma. Interleukin-37 (IL-37), a cytokine that effectively inhibits innate and adaptive immunity, has powerful anti-inflammatory and anti-tumor effects. Several single nucleotide polymorphisms (SNPs) in the IL37 gene are genetic predictive risk factors for HBV infection and HBV-mediated liver disease progression. However, different ethnic groups may have different allele frequencies and linkage disequilibrium structures. The effect of SNPs in IL37 on HBV infection and its relationship with different clinical outcomes have not been clarified among the Han people in southern China. Based on in silico functional prediction and previously reported in the literature to be potentially associated with diseases, we screened seven potentially functional SNPs (rs3811046, rs3811047, rs2723176, rs2723186, rs4611652, rs4392270, and rs4241122) located in the IL37 genomic region and 3-kb upstream and downstream of the gene body. 1,582 subjects were included in the study, including 747 patients with HBV-related liver disease, 405 patients who cleared HBV, and 430 healthy controls. The seven SNPs were genotyped using the SNaPshot SNP assay, and co-dominant, dominant, and recessive models were used to explore the association of each SNP with HBV infection and clinical outcomes after HBV infection. The rs4241122 demonstrated a significant association with both HBV infection and its clinical outcomes, with the GG genotype identified as an independent protective factor for spontaneous clearance of HBV. The rs2723186 and rs4392270 were also significantly associated with HBV clearance under specific genetic models. Furthermore, rs3811046 and rs3811047 were correlated with the progression of liver abnormalities following HBV infection. Our data suggests that SNPs at the IL37 locus are associated with susceptibility to HBV infection and clinical outcomes after HBV infection.

Keywords: Chinese; Hepatitis B virus; Interleukin-37; Single-nucleotide polymorphisms; SnaPshot
Grants and funding:

This study was partially supported by the Guangzhou Health Technology Project (No. 20231A011116), the Huadu District Basic and Applied Basic Research Joint Funding Project (District-Hospital Collaboration), Guangzhou (No. 24HDQYLH12) and Guangzhou Medical Key Subject Construction Project [2025-2027].

Conflicts of interest:

The authors have no potential conflict of interest to declare with respect to the research, authorship, and/or publication of this article.

Received: January 24, 2025; Revised: August 26, 2025; Accepted: October 24, 2025; Prepublished online: October 30, 2025 

Download citation

References

  1. Al-Anazi MR, Matou-Nasri S, Al-Qahtani AA, Alghamdi J, Abdo AA, Sanai FM, et al. (2019). Association between IL-37 gene polymorphisms and risk of HBV-related liver disease in a Saudi Arabian population. Sci Rep 9(1): 7123. DOI: 10.1038/s41598-019-42808-4. Go to original source... Go to PubMed...
  2. Allam G, Gaber AM, Othman SI, Abdel-Moneim A (2020). The potential role of interleukin-37 in infectious diseases. Int Rev Immunol 39(1): 3-10. DOI: 10.1080/08830185.2019.1677644. Go to original source... Go to PubMed...
  3. Asín-Prieto E, Parra-Guillen ZP, Mantilla JDG, Vandenbossche J, Stuyckens K, de Trixhe XW, et al. (2019). Immune network for viral hepatitis B: Topological representation. Eur J Pharm Sci 136: 104939. DOI: 10.1016/j.ejps.2019.05.017. Go to original source... Go to PubMed...
  4. Ben Selma W, Laribi AB, Alibi S, Boukadida J (2021). Association of an IFN-γ variant with susceptibility to chronic hepatitis B by the enhancement of HBV DNA replication. Cytokine 143: 155525. DOI: 10.1016/j.cyto.2021.155525. Go to original source... Go to PubMed...
  5. Cheng H, Sun F, Ouyang Y, Li C (2023). Correlation analysis of IL-37 gene polymorphisms and susceptibility to chronic HBV infection among Han people in Central China. Int J Immunogenet 50(6): 299-305. DOI: 10.1111/iji.12638. Go to original source... Go to PubMed...
  6. Cheng ST, Yuan D, Liu Y, Huang Y, Chen X, Yu HB, et al. (2018). Interleukin-35 Level Is Elevated in Patients with Chronic Hepatitis B Virus Infection. Int J Med Sci 15(2): 188-194. DOI: 10.7150/ijms.21957. Go to original source... Go to PubMed...
  7. Dondeti MF, Abdelkhalek MS, El-Din Elezawy HM, Alsanie WF, Raafat BM, Gamal-Eldeen AM, Talaat RB (2022). Association between interferon-gamma (IFN-γ) gene polymorphisms (+874A/T and +2109A/G), and susceptibility to hepatitis B viral infection (HBV). J Appl Biomed 20(1): 37-43. DOI: 10.32725/jab.2022.001. Go to original source... Go to PubMed...
  8. Fang P, Cai D, Du L, Shen F, Zhang C, Li M (2021). Relationship Between Polymorphism of Thrombin-Activatable Fibrinolysis Inhibitor Gene +1040C/T and a Cohort of Chinese Women With Recurrent Spontaneous Abortion. Clin Appl Thromb Hemost 27: 10760296211029720. DOI: 10.1177/10760296211029720. Go to original source... Go to PubMed...
  9. Gu M, Jin Y, Gao X, Xia W, Xu T, Pan S (2023). Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process. Front Immunol 14: 1278521. DOI: 10.3389/fimmu.2023.1278521. Go to original source... Go to PubMed...
  10. Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, et al. (2019). Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol 4(6): 466-476. DOI: 10.1016/S2468-1253(19)30042-1. Go to original source... Go to PubMed...
  11. Jiang B, Zhou Y, Liu Y, He S, Liao B, Peng T, et al. (2023). Research Progress on the Role and Mechanism of IL-37 in Liver Diseases. Semin Liver Dis 43(3): 336-350. DOI: 10.1055/a-2153-8836. Go to original source... Go to PubMed...
  12. Li M, Zu J (2019a). The review of differential equation models of HBV infection dynamics. J Virol Methods 266: 103-113. DOI: 10.1016/j.jviromet.2019.01.014. Go to original source... Go to PubMed...
  13. Li TY, Yang Y, Zhou G, Tu ZK (2019b). Immune suppression in chronic hepatitis B infection associated liver disease: A review. World J Gastroenterol 25(27): 3527-3537. DOI: 10.3748/wjg.v25.i27.3527. Go to original source... Go to PubMed...
  14. Li Y, Xu A, Jia S, Huang J (2019c). Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma. Oncol Lett 17(5): 4222-4228. DOI: 10.3892/ol.2019.10127. Go to original source... Go to PubMed...
  15. Liu H, Zheng R, Wang P, Yang H, He X, Ji Q, et al. (2017). IL-37 Confers Protection against Mycobacterial Infection Involving Suppressing Inflammation and Modulating T Cell Activation. PLoS One 12(1): e0169922. DOI: 10.1371/journal.pone.0169922. Go to original source... Go to PubMed...
  16. Liu Z, Lin C, Mao X, Guo C, Suo C, Zhu D, et al. (2023). Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut 72(12): 2354-2363. DOI: 10.1136/gutjnl-2023-330691. Go to original source... Go to PubMed...
  17. Meng JP, Luo P, Bai Y, Cui F (2020). Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection. J Int Med Res 48(1): 300060519884157. DOI: 10.1177/0300060519884157. Go to original source... Go to PubMed...
  18. Molaei V, Fattahi MR, Haghshenas MR, Hosseini SY, Malekhosseini SA, Sarvari J (2023). Polymorphism Analysis of Interleukin-18 and Interleukin-37 Genes in Hepatitis B Infections with Different Outcomes: A Preliminary Report from an Iranian Population. Asian Pac J Cancer Prev 24(2): 411-416. DOI: 10.31557/APJCP.2023.24.2.411. Go to original source... Go to PubMed...
  19. Munkongdee T, Tongsima S, Ngamphiw C, Wangkumhang P, Peerapittayamongkol C, Hashim HB, et al. (2021). Predictive SNPs for β0-thalassemia/HbE disease severity. Sci Rep 11(1): 10352. DOI: 10.1038/s41598-021-89641-2. Go to original source... Go to PubMed...
  20. Su Z, Tao X (2021). Current Understanding of IL-37 in Human Health and Disease. Front Immunol 12: 696605. DOI: 10.3389/fimmu.2021.696605. Go to original source... Go to PubMed...
  21. Tan H, Deng B, Yu H, Yang Y, Ding L, Zhang Q, et al. (2016). Genetic analysis of innate immunity in Behcet's disease identifies an association with IL-37 and IL-18RAP. Sci Rep 6: 35802. DOI: 10.1038/srep35802. Go to original source... Go to PubMed...
  22. Wang M, Wang Y, Feng X, Wang R, Wang Y, Zeng H, et al. (2017). Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center. Int J Infect Dis 65: 15-21. DOI: 10.1016/j.ijid.2017.09.003. Go to original source... Go to PubMed...
  23. Yan N, Meng S, Song RH, Qin Q, Wang X, Yao Q, et al. (2015). Polymorphism of IL37 gene as a protective factor for autoimmune thyroid disease. J Mol Endocrinol 55(3): 209-218. DOI: 10.1530/JME-15-0144. Go to original source... Go to PubMed...
  24. Yang G, Wan P, Zhang Y, Tan Q, Qudus MS, Yue Z, et al. (2022). Innate Immunity, Inflammation, and Intervention in HBV Infection. Viruses 14(10): 2275. DOI: 10.3390/v14102275. Go to original source... Go to PubMed...
  25. Yin D, Naji DH, Xia Y, Li S, Bai Y, Jiang G, et al. (2017). Genomic Variant in IL-37 Confers A Significant Risk of Coronary Artery Disease. Sci Rep 7: 42175. DOI: 10.1038/srep42175. Go to original source... Go to PubMed...

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.